Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada

Aim: This study examined treatment patterns, survival outcomes and healthcare costs related to hepatocellular carcinoma (HCC) in British Columbia. Methods: The study utilized data from two physician databases (HCC and MOTION) and the provincial British Columbia transplant database. Results: The analysis revealed diverse treatment approaches and identified the varying treatment journeys of patients. Liver transplant and systemic therapies demonstrated improved survival rates. However, there was a scarcity of Canadian-specific cost data. Conclusion: The research emphasizes the complexities of managing HCC and underscores the need for personalized treatment strategies to enhance patient outcomes. These findings contribute valuable insights into HCC management and provide a foundation for future studies and interventions aimed at optimizing care and resource allocation. This study examined HCC treatment patterns, survival, and healthcare costs in British Columbia. Data revealed diverse treatment modalities and etiologies. Liver transplant and systemic therapies were associated with improved survival. #HCC #TreatmentPatterns #Survival #Costs This study looked at how people diagnosed with liver cancer in British Columbia were treated, how long they lived and how much treatment cost. Treatment records were reviewed, and depending on the extent of the disease, treatments could include surgery, treatments directed at the liver and/or anti-cancer therapy. The average survival time varied from 21-33 months, with an average cost per patient of $94,000. This helps us understand the patient journey and future studies would include current treatment options.